GRI · GRI Bio, Inc.
$1.48
-0.03 (-1.99%)
At close · Jul 22
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$2.62M
Shares
1.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Leanne Kelly | CFO | $469,420 |
| Vipin Kumar Chaturvedi | Chief Scientific Officer | $419,420 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Baker | CEO | $1,297,051 |
| W. Marc Hertz | CEO | $785,764 |
| Leanne Kelly | CFO | $646,617 |
| Albert Agro | Chief Medical Officer | $406,986 |
| Vipin Kumar Chaturvedi | Chief Scientific Officer | $302,853 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Baker | CEO | $919,564 |
| Leanne Kelly | CFO | $673,541 |
| Penny S. Toren | Former Senior Vice President, Regulatory Affairs & Program Management | $298,337 |
| Albert Agro | Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David Baker | CEO | $826,880 |
| Leanne Kelly | CFO | $498,859 |
| Penny S. Toren | Former Senior Vice President, Regulatory Affairs & Program Management | $359,373 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David Baker | CEO | $669,149 |
| Penny S. Toren | Former Senior Vice President, Regulatory Affairs & Program Management | $358,199 |